Navigation Links
NanoSmart™ Pharmaceuticals, Inc. Receives Patent Allowance for Tumor Targeting Platform Technology
Date:8/16/2010

ORANGE COUNTY, Calif., Aug. 16 /PRNewswire/ -- NanoSmart™ Pharmaceuticals, Inc., a California corporation developing novel biopharmaceuticals, is pleased to report that it has received a Notice of Allowance for a US patent on its proprietary cancer tumor targeting technology.

"We have taken an approach to targeting tumors that is different from other companies," said Dr. Henry Smith, CEO of the company. "While most of cancer research has focused on developing antibodies to specific tumor antigens, we realized that it was possible to target normal cellular material that is inappropriately expressed within the tumor mass.  Many tumors contain areas of necrosis where dead cells have ruptured and emptied their intracellular material into the extracellular environment. We have developed a fully-human antibody to target this material, and use it as an agent to transport cancer drugs to the tumor site where they would have the most effect."

About the technology:

NanoSmart™ is developing a novel anti-tumor targeting platform based on fully-human autoimmune antibodies. These antibodies can target areas of necrosis found in many different types of cancer. This cancer tumor targeting system represents a versatile platform technology with many advantages, including improved localization of cancer therapeutics leading to increased safety and efficacy. By combining these antibodies with different cancer drugs, NanoSmart™ has the potential to develop a very large number of novel biopharmaceuticals.

"There are only a handful of companies that have succeeded in developing antibodies that can target tumors," said Dr. Smith. "We are pleased that our company has been successful in its approach and that we have achieved a very significant milestone in securing our intellectual property. The opportunity to help millions of cancer patients doesn't happen too often in one's lifetime."

NanoSmart™ Pharmaceuticals, Inc. is a privately-held company engaged in developing novel methods to treat cancer and other diseases. The company is focused on using its patented tumor targeting antibodies to develop a variety of biopharmaceuticals to treat many different types of cancer. This press release may contain forward-looking statements regarding future events. There can be no assurance that such development efforts will succeed; or that the novel biopharmaceuticals will receive regulatory clearance or achieve commercial success.For more information contact us at (949) 340-7261E-mail us at info@nanosmartpharmaceuticals.comInvestor Relations: (310) 951-3282Please visit our website:  www.nanosmartpharmaceuticals.com


'/>"/>
SOURCE NanoSmart Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC
3. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
4. Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team
5. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
6. Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group
7. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
8. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
9. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
10. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
11. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... Washington, USA, and CARDIFF, UK (PRWEB) , ... June 23, 2017 ... ... Lab (LANL), and Brian Lula, president of Physik Instrumente USA, have been selected as ... optics and photonics . , The two have been invited along with other honorees ...
(Date:6/22/2017)... ... June 21, 2017 , ... RMC Pharmaceutical Solutions, ... engages Timothy Reinhardt to manage the new site. , Tim has 25 years ... his most recent role as the Director of Manufacturing and Supplier Quality Assessment. ...
(Date:6/22/2017)... , ... June 22, 2017 , ... ... network RegMedNet has produced a Spotlight series on “Cell ... reviews and perspectives by leading experts on the unique regulatory challenges of stem ...
(Date:6/22/2017)... (PRWEB) , ... June 22, 2017 , ... Charm Sciences, ... validation. The AMPH test was determined to be appropriate as a screening test at ... interpretation, on the Charm EZ system, and the Charm EZ Lite system. These systems ...
Breaking Biology Technology:
(Date:5/6/2017)... , May 5, 2017 ... just announced a new breakthrough in biometric authentication ... exploits quantum mechanical properties to perform biometric authentication. These ... smart semiconductor material created by Ram Group and ... finance, entertainment, transportation, supply chains and security. Ram ...
(Date:4/13/2017)... MONICA, Calif. , April 13, 2017 ... New York will feature emerging and evolving ... Summits. Both Innovation Summits will run alongside the expo ... of speaker sessions, panels and demonstrations focused on trending ... coast,s largest advanced design and manufacturing event will take ...
(Date:4/11/2017)... , April 11, 2017 NXT-ID, Inc. ... technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate governance ... Gino ... we look forward to their guidance and benefiting from their ...
Breaking Biology News(10 mins):